Literature DB >> 9649423

Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants.

G Puntoriero1, A Meola, A Lahm, S Zucchelli, B B Ercole, R Tafi, M Pezzanera, M U Mondelli, R Cortese, A Tramontano, G Galfre', A Nicosia.   

Abstract

The hypervariable region 1 (HVR1) of the putative envelope protein E2 of hepatitis C virus (HCV) is the most variable antigenic fragment in the whole viral genome and is mainly responsible for the large inter-and intra-individual heterogeneity of the infecting virus. It contains a principal neutralization epitope and has been proposed as the major player in the mechanism of escape from host immune response. Since anti-HVR1 antibodies are the only species shown to possess protective activity up to date, developing an effective prevention therapy is a very difficult task. We have approached the problem of HVR1 variability by deriving a consensus profile from >200 HVR1 sequences from different viral isolates and used it as a template to generate a vast repertoire of synthetic HVR1 surrogates displayed on M13 bacteriophage. This library was affinity selected using many different sera from infected patients. Phages were identified which react very frequently with patients' sera and bind serum antibodies that cross-react with a large panel of HVR1 peptides derived from natural HCV variants. When injected into experimental animals, the 'mimotopes' with the highest cross-reactivity induced antibodies which recognized the same panel of natural HVR1 variants. In these mimotopes we identified a sequence pattern responsible for the observed cross-reactivity. These data may hold the key for future development of a prophylactic vaccine against HCV.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9649423      PMCID: PMC1170689          DOI: 10.1093/emboj/17.13.3521

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  43 in total

1.  Sequence analysis of the hepatitis C virus genome recovered from serum, liver, and peripheral blood mononuclear cells of infected chimpanzees.

Authors:  Y K Shimizu; H Igarashi; T Kanematu; K Fujiwara; D C Wong; R H Purcell; H Yoshikura
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 2.  To C or not to C: these are the questions.

Authors:  H J Alter
Journal:  Blood       Date:  1995-04-01       Impact factor: 22.113

Review 3.  Epitope discovery using peptide libraries displayed on phage.

Authors:  R Cortese; F Felici; G Galfre; A Luzzago; P Monaci; A Nicosia
Journal:  Trends Biotechnol       Date:  1994-07       Impact factor: 19.536

4.  A method to predict functional residues in proteins.

Authors:  G Casari; C Sander; A Valencia
Journal:  Nat Struct Biol       Date:  1995-02

5.  Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant.

Authors:  A Weiner; A L Erickson; J Kansopon; K Crawford; E Muchmore; A L Hughes; M Houghton; C M Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

6.  Evolution and selection of hepatitis C virus variants in patients with chronic hepatitis C.

Authors:  M Kurosaki; N Enomoto; F Marumo; C Sato
Journal:  Virology       Date:  1994-11-15       Impact factor: 3.616

7.  Influence of antibodies to the hypervariable region of E2/NS1 glycoprotein on the selective replication of hepatitis C virus in chimpanzees.

Authors:  M Kojima; T Osuga; F Tsuda; T Tanaka; H Okamoto
Journal:  Virology       Date:  1994-11-01       Impact factor: 3.616

8.  Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities.

Authors:  E Silini; F Bono; A Cividini; A Cerino; S Bruno; S Rossi; G Belloni; B Brugnetti; E Civardi; L Salvaneschi
Journal:  Hepatology       Date:  1995-02       Impact factor: 17.425

9.  Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses.

Authors:  L J van Doorn; I Capriles; G Maertens; R DeLeys; K Murray; T Kos; H Schellekens; W Quint
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

10.  Derivation of vaccines from mimotopes. Immunologic properties of human hepatitis B virus surface antigen mimotopes displayed on filamentous phage.

Authors:  A Meola; P Delmastro; P Monaci; A Luzzago; A Nicosia; F Felici; R Cortese; G Galfrè
Journal:  J Immunol       Date:  1995-04-01       Impact factor: 5.422

View more
  44 in total

1.  Epitope mapping of trans-sialidase from Trypanosoma cruzi reveals the presence of several cross-reactive determinants.

Authors:  T A Pitcovsky; J Mucci; P Alvarez; M S Leguizamón; O Burrone; P M Alzari; O Campetella
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

Review 2.  Immunopathogenesis of viral hepatitis.

Authors:  M U Mondelli
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

3.  Molecular characterization of a full genome Turkish hepatitis C virus 1b isolate (HCV-TR1): a predominant viral form in Turkey.

Authors:  Esra Yildiz; Asli Oztan; Funda Sar; Ergun Pinarbasi; Rengul Cetin-Atalay; Hikmet Akkiz; Mehmet Ozturk
Journal:  Virus Genes       Date:  2002-10       Impact factor: 2.332

4.  Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer.

Authors:  S Zucchelli; S Capone; E Fattori; A Folgori; A Di Marco; D Casimiro; A J Simon; R Laufer; N La Monica; R Cortese; A Nicosia
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

5.  Significance of pretreatment analysis of hepatitis C virus genotype 1b hypervariable region 1 sequences to predict antiviral outcome.

Authors:  Catherine Gaudy; Alain Moreau; Pascal Veillon; Stephanie Temoin; Francoise Lunel; Alain Goudeau
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

Review 6.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

7.  Vaccination with dendritic cells pulsed with hepatitis C pseudo particles induces specific immune responses in mice.

Authors:  Kilian Weigand; Franziska Voigt; Jens Encke; Birgit Hoyler; Wolfgang Stremmel; Christoph Eisenbach
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

Review 8.  Variability or conservation of hepatitis C virus hypervariable region 1? Implications for immune responses.

Authors:  Mario U Mondelli; Antonella Cerino; Annalisa Meola; Alfredo Nicosia
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

9.  Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes.

Authors:  Nicasio Mancini; Roberta A Diotti; Mario Perotti; Giuseppe Sautto; Nicola Clementi; Giovanni Nitti; Arvind H Patel; Jonathan K Ball; Massimo Clementi; Roberto Burioni
Journal:  PLoS One       Date:  2009-12-11       Impact factor: 3.240

10.  Purification of polyclonal anti-conformational antibodies for use in affinity selection from random peptide phage display libraries: a study using the hydatid vaccine EG95.

Authors:  A J Read; C G Gauci; M W Lightowlers
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-03-28       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.